Grünenthal
Tracked across 3 events · 28 articles · First seen Jun 29, 2026 · Last active Jul 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Grünenthal successfully completed a Phase I trial for its NOP agonist, demonstrating its safety and tolerability. This positive development allows the company to advance the compound to Phase II trials, potentially leading to a new pain treatment option and enhancing Grünenthal's market position in pain management.
Jun 29, 2026 · 9 articles
Regulatory
Impact: Grünenthal received FDA designations for its investigational drug tegacorat, a positive regulatory milestone that may enhance its pipeline value and future revenue prospects.
Jul 08, 2026 · 10 articles
Business
Impact: Grünenthal is the main actor, joining CNATM to enhance its oligonucleotide capabilities for pain and neurological diseases. This strengthens its R&D pipeline in genetic medicine.
Jul 16, 2026 · 9 articles
ERGEN INTELLIGENCE
Track Grünenthal live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard